Clinical trial
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
NCT05843162 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- June 1, 2023
- Completion date
- December 31, 2023
- Enrollment
- 116 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.